A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: The West Japan Study Group for Lung Cancer Surgery (WJSG) - The 4th study

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 75-80

  Nakagawa, M ^a   Tanaka, F ^a   Tsubota, N ^b   Ohta, M ^c   Takao, M ^d   Wada, H ^a   Oda, M ^e   Misaki, T ^f   Fujino, S ^g   Narita, N ^h   Kounoike, Y ^h   Namikawa, S ^d   Monden, Y ⁱ   Uyama, T ⁱ   Saito, Y ^j   Kawakami, M ^k   Shimizu, N ^l   Okimoto, N ^m   Yamakido, M ⁿ   Sasaki, T ^o   Hamano, K ^p   Shirouzu, K ^q   Hayashi, A ^q   Nagayasu, T ^r   Aiko, K ^s   Naitou, Y ^t   Maebeya, S ^t   Maeda, M ^u   Nakamura, K ^u   Ishikawa, K ^c   Senou, N ^v   Tamada, J ^w   Kitano, M ^x   Tatsumi, A ^x   Matsubara, Y ^y   Noto, H ^z   Yamanaka, A ^aa   Umemori, Y ^ab   Sugi, K ^ab   Osako, T ^ac   Miyamoto, N ^ad   Takashima, S ^ae   Tanaka, K ^af   Nishiwaki, K ^ag   Itoi, K ^ah   Miyamoto, Y ^ai   Morita, J ^aj   Nishiyama, K ^ak   Isowa, N ^al   more..

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^c National Hospital Organization Okinawa National Hospital   (Japan)

^d MIE UNIVERSITY   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^h NARA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOKUSHIMA   (Japan)

^j KANSAI MEDICAL UNIVERSITY   (Japan)

^k OSAKA MEDICAL COLLEGE   (Japan)

^l OKAYAMA UNIVERSITY   (Japan)

^m KAWASAKI MEDICAL SCHOOL   (Japan)

ⁿ HIROSHIMA UNIVERSITY   (Japan)

^o SHIMANE UNIVERSITY   (Japan)

^p YAMAGUCHI UNIVERSITY   (Japan)

^q KURUME UNIVERSITY   (Japan)

^r NAGASAKI UNIVERSITY   (Japan)

^s KAGOSHIMA UNIVERSITY   (Japan)

^t WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^u KAGAWA UNIVERSITY   (Japan)

^v HIROSHIMA CITY HOSPITAL   (Japan)

^w KURASHIKI CENTRAL HOSPITAL   (Japan)

^x TENRI HOSPITAL   (Japan)

^y KYOTO KATSURA HOSPITAL   (Japan)

^z TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^aa FUKUI PREFECTURAL HOSPITAL   (Japan)

^ab NATIONAL SANYO HOSPITAL   (Japan)

^ac KYOTO CITY HOSPITAL   (Japan)

^ad Kochi Municipal Hospital   (Japan)

^ae NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^af UNIVERSITY OF FUKUI   (Japan)

^ag NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^ah HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^ai NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^aj TAKAMATSU RED CROSS HOSPITAL   (Japan)

^ak KYOTO PREFECTURAL UNIVERSITY   (Japan)

^al MATSUE RED CROSS HOSPITAL   (Japan)

more..

Author keywords

Adenocarcinoma; Adjuvant chemotherapy; Lung cancer; Squamous cell carcinoma; Surgery; UFT

Indexed keywords

FLUOROURACIL DERIVATIVE; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; JAPAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 19944427132     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi008     Document Type: Article

References (30)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 116: 1710-1717.
2. Naruke T, Tsuchiya R, Kondo H et al. Implication of staging in lung cancer. Chest 1997; 112: 242s-248s.
3. Tanaka F, Yanagihara K, Otake Y et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-nodemetastasis classification and its time trend. Eur J Cardiothorac Surg 2000; 18: 147-155.
4. Tanaka F, Yanagihara K, Ohtake Y et al. Time trends and survival after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1997; 12: 372-379.
5. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352: 257-263.
6. Niiranen A, Niitamo-Korhonen S, Kouri M et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 1992; 10: 1927-1932.
7. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 1993; 85: 299-306.
8. Ohta M, Tsuchiya R, Shimoyama M et al. Adjuvant chemotherapy for completely resected stage non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993; 106: 703-708.
9. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000; 343: 1217-1222.
10. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 1453-1461.
11. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
12. Arriagada R, Bergman B, Dunant A et al. and International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
13. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996; 14: 1048-1054.
14. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tertahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
15. Ikenaka K, Shirasaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353-359.
16. 1-(2′-Tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085-2088.
17. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89 (Suppl 4): 225s-233s.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
19. The Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer, 3rd edition. Tokyo: Kanehara 1987.
20. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163-170.
21. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 187-220.
22. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721.
23. Shirakusa T, Kobayashi K. and Japanese Joint Committee of Lung Cancer Registry. Lung cancer in Japan: Analysis of lung cancer registry for resected cases in 1994. Jpn J Lung Cancer 2002; 42: 555-566.
24. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995; 75: 2844-2852.
25. Kodama K, Higashiyama M, Yokouchi H et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer 2001; 33: 17-25.
26. Shimizu E, Kimura K, Sone S et al. A phase II study of UFT in non-small cell lung cancer. Jpn J Cancer Chemother 1986; 13: 2970-2973.
27. Yonekura K, Basaki Y, Chikahisa L et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: 2185-2191.
28. Tanaka F, Otake Y, Yanagihara K et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001; 84: 263-269.
29. Tanaka F, Yanagihara K, Otake Y et al. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci 2004; 95: 371-376.
30. Hamada C, Ohta M, Wada H et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. Proc ASCO 2004; 23: 615 (Abstr 7002).